CD44 and ovarian carcinoma: For instance, miR-34a repressed CD44 expression in prostate CD44+ CSCs, resulting in metastasis and regeneration inhibition [107], and miR-199a-mediated targeting of CD44 in ovarian cancer-initiating cells suppressed tumourigenesis and multidrug resistance [108].